NovMetaPharma Co., Ltd. (XKON: 229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,050.00
-30.00 (-0.59%)
Sep 10, 2024, 9:00 AM KST
-31.94%
Market Cap 45.26B
Revenue n/a
Net Income n/a
Shares Out 8.96M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,118
Open 5,080.00
Previous Close 5,080.00
Day's Range 4,850.00 - 5,100.00
52-Week Range 4,505.00 - 10,250.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile

News

There is no news available yet.